Roche forges new diagnostic alliance
The Basel-based pharmaceuticals company, Roche, has formed an alliance with the US Millennium group to develop diagnostic products for rheumatoid arthritis.
Under the three-year deal, Millennium will receive a licensing fee, royalties and funding for research. Roche gets certain research and development rights and will market products resulting from the alliance.
"The combination of Roche's world-class strength in diagnostics with Millennium's strong position in genomics and proteomics will bring revolutionary diagnostic products to the market," said Heino von Prondzynski, the head of Roche's diagnostics division.
No financial details of the agreement have been released.
Swissinfo with agencies
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at firstname.lastname@example.org.